Drugs

JJLBRO

FDA issued a warning letter to JJLBRO (Antalya, Turkey) on Jun 17, 2026, citing 21 CFR 201.128. Subject: Unapproved New Drugs, Misbranded.

From the letter: ““Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended…”

Antalya, TurkeyIssued Jun 17, 2026Posted Jun 23, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
2 findings · 2 issue types
Response due
Fifteen (15) business days of receipt
FDA asks for
3 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketing · 21 CFR 201.128Products are drugs due to intended use claims for treating disease or affecting body function.
“Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.
02Registration, listing & premarketProducts are unapproved new drugs without required FDA-approved applications.
No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs.

What FDA requested

  • Provide specific steps taken to correct violations and prevent recurrence
  • Include copies of related documentation in written response
  • Provide information demonstrating products are not in violation if available

FDA Warning Letter

53 paragraphs · 10 sections

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedJune 17, 2026
Reference729873
AddressedJJLBRO and Romvy E-Ticaret Limited Sirketi

1Introduction

1 paragraph

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

2FDA Review

2 paragraphs

Violations were identified and documented during a review of your website https://jjlbro.com/ in May 2026. We also reviewed your Amazon storefront in May 2026.1 Based on our review, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

This review was conducted as part of FDA's public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.

3Violations of the Federal Food, Drug, and Cosmetic Act

1 paragraph

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.

4Unapproved New Drug Violations

1 paragraph

Based on a review of your website, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

5Men’s Foreskin Repair Gel

4 paragraphs

On the webpage https://jjlbro.com/products/mens-extra-power-foreskin-repair-enhancement-gel?variant=41998671478878:

“DOUBLE LINE CARE, DIRECT HIT PHIMOSIS”

“ABSORPTION OF INTERNAL ADHESIONS”

“TO PROMOTE THE VITALITY OF PRIVATE CELLS FROM THE CONGENITAL PHIMOSIS”

6Size’Up Chrono Erect

3 paragraphs

On the webpage https://jjlbro.com/products/mens-size-up-chrono-erect-enlargement-cream-extra-power-massage-gel-oil-for-huge-thickness-strength-and-prolonged-performance?variant=41998765916254:

“Proven Size Enhancement: Clinically . . . shown to help promote blood flow and stimulate cell growth, leading to visible results in size enhancement with consistent use.”

“Prolonged Performance: Men’s Size Up Chrono Erect Enlargement Cream supports prolonged performance by stimulating circulation and energy flow, improving stamina and endurance.”

7Penile Health Cream

8 paragraphs

On the webpage https://jjlbro.com/products/male-performance-med3000-enhancement-gel?variant=41998765850718:

“BOOST MUSCLE STRENGTH”

“ENHANCES LIBIDO AND PLEASURE”

“INCREASE ENERGY AND STAMINA”

“IMPROVE MALE REPRODUCTIVE HEALTH”

“Naturally Boosts Energy, Libido, Fertility, Mood, and Hormonal Balance.”

“Enhances intimacy, Improves Blood Flow, and Elevates Performance.”

“Believed to Support Brain Health, Soothe Pain, and Reinforce Masculinity.”

8Men’s External Delayed Spray

5 paragraphs

On the webpage https://jjlbro.com/products/mens-best-external-delay-enhancement-spray:

“Prolonged Performance: Allows for extended enjoyment and satisfaction”

“Quick-Acting Formula: Starts working within minutes for immediate results, so you’re always prepared.”

“PREMATURE EJACULATION MAKES MEN MISERABLE”

“MAY STIMULATE CAVERNOUS BODIES, REPRODUCTIVE GLANDS, NERVOUS SYSTEM IT MAKES IT PLAY A NORMAL FUNCTION, NOT ONLY TO HELP WITH OVERTIME, BUT ALSO TO HELP THE ERECTION FUNCTION”

9Men’s Penis XXL Care Cream

8 paragraphs

On the webpage https://jjlbro.com/products/men-s-care-ultra-enlargement-cream-jjlbro-huge-xxl-extra-strength-growth-cream-for-mens-size-power-xxl-care?variant=41998751563870:

“SEXUAL EXCITEMENT”

“LAST LONGER”

“LARGER SIZE”

“HUGE”

“Proven Size Enhancement: Clinically . . . shown to help promote blood flow and stimulate cell growth, leading to visible results in size enhancement with consistent use”

“Prolonged Performance . . . by stimulating circulation and energy flow, improving stamina and endurance”

“Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

10Conclusion

3 paragraphs
Response requested

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure sustained compliance so that these violations and any others do not occur.Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729873” in the subject line of the email.

If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.

Please note FDA posts warning letters on www.fda.gov.

Sincerely,/S/

Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

__________________________

1 https://www.amazon.com/s?i=merchant-items&me=A327E0NFTQVK94&marketplaceID=ATVPDKIKX0DER&qid=1778778461&xpid=ogniWslo1h6zF&ref=sr_pg_1

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Antalya, Turkey
Letter posted date
Jun 23, 2026
Letter issue date
Jun 17, 2026
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
15 business days after receipt of this letter
Read the source clause
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
Record length
936 words · 0 recorded redactions
Published status
No published close-out
FDA reference
729873
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.